Trials / Completed
CompletedNCT05518708
A Study in Healthy Men to Test How Different Doses of BI 3032950 Are Tolerated
A Phase I Single-blind, Randomised, Placebo-controlled, Parallelgroup Design Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Harmacodynamics of Single Rising Doses of BI 3032950 Administered as Intravenous Infusion (Part A) or Subcutaneous Injection (Part B) to Healthy Male Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 94 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The main objectives of this trial are to investigate safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of BI 3032950 in healthy male subjects following intravenous (Part A) or subcutaneous (Part B) administration of single rising doses.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 3032950 | BI 3032950 |
| DRUG | Placebo | Placebo |
Timeline
- Start date
- 2022-09-27
- Primary completion
- 2023-09-21
- Completion
- 2023-09-21
- First posted
- 2022-08-29
- Last updated
- 2023-09-26
Locations
1 site across 1 country: Belgium
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05518708. Inclusion in this directory is not an endorsement.